Search

Your search keyword '"Carlos Graux"' showing total 5 results
Start Over Author "Carlos Graux" Journal leukemia
5 results on '"Carlos Graux"'

1. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Author

Douglas V. Faller, Justin M. Watts, Atanas Radinoff, Jill A Bell, Lionel Ades, Dan Zhao, Maria Diez Campelo, Nikolay Tzvetkov, Montserrat Arnan Sangerman, Robert J. Fram, Sharon Friedlander, Dominik Selleslag, Joshua F. Zeidner, Jane L. Liesveld, Patricia Font Lopez, Carlos Graux, Marco Cerrano, Mikkael A. Sekeres, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Letter, business.industry, Azacitidine, Hematology, Acute myeloid leukaemia, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Randomized controlled trials, business, Myelodysplastic syndrome, medicine.drug
Abstract

TO THE EDITOR : There is a critical unmet need for novel treatments for higher-risk myelodysplastic syndromes (MDS), higher-risk chronic myelomonocytic leukemia (CMML), and low-blast (LB) acute myeloid leukemia (AML). For patients ineligible for stem cell transplant (SCT), standard therapy with hypomethylating agents, such as azacitidine and decitabine, is not curative, with most patients relapsing within 2 years. [...]

Published
2021

2. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

Author

Zita Borbényi, Suddhasatta Acharyya, Karen W.L. Yee, Je-Hwan Lee, Massimo Breccia, S. Ide, Árpád Illés, Alan Macwhannell, Carlos Graux, Miklos Egyed, Nancy Zhu, David Valcárcel, James D. Cavenagh, Reinhard Stauder, Huda Salman, Daniel J. DeAngelo, Mikkael A. Sekeres, M. Marker, Oliver G. Ottmann, G. Garcia-Manero, Lucien Gazi, and Pierre Fenaux

Subjects
0301 basic medicine, Male, Cancer Research, Myeloid, Indoles, Administration, Oral, Kaplan-Meier Estimate, Hydroxamic Acids, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Bone Marrow, Antineoplastic Combined Chemotherapy Protocols, Panobinostat, Aged, 80 and over, Leukemia, Myelomonocytic, Chronic, Hematology, Orvostudományok, Middle Aged, 3. Good health, Leukemia, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Azacitidine, Original Article, Female, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Chronic myelomonocytic leukemia, Klinikai orvostudományok, 03 medical and health sciences, Internal medicine, medicine, Humans, neoplasms, Aged, business.industry, Myelodysplastic syndromes, medicine.disease, Demethylating agent, Regimen, 030104 developmental biology, chemistry, Myelodysplastic Syndromes, business
Abstract

Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is

Published
2017

3. Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia

Author

Peter Meeus, Peter Vandenberghe, Chrystele Bilhou-Nabera, Iwona Wlodarska, A. Van Hoof, Nancy Boeckx, Bernard Chatelain, Friedel Nollet, Vincent Madoe, Carlos Graux, Ann Janssens, Lucienne Michaux, E. Van Den Neste, Katrina Rack, and Natalie Put

Subjects
Adult, Male, Cancer Research, Poor prognosis, Chronic lymphocytic leukemia, Chromosomal translocation, Biology, Translocation, Genetic, Text mining, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Aged, 80 and over, Chromosomes, Human, Pair 14, business.industry, Hematology, Middle Aged, Prognosis, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, Oncology, Immunology, Cancer research, Female, Chromosomes, Human, Pair 18, business
Abstract

Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia

Published
2009

4. Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia

Author

Peter Vandenberghe, Idoya Lahortiga, K. De Keersmaecker, Johan Maertens, Carlos Graux, Jan Cools, and Peter Marynen

Subjects
Hybrid gene, Cancer Research, medicine.medical_specialty, Oncogene Proteins, Fusion, Lymphoblastic Leukemia, Biology, Gastroenterology, hemic and lymphatic diseases, Internal medicine, Acute lymphocytic leukemia, mental disorders, medicine, Humans, Leukemia-Lymphoma, Adult T-Cell, Receptor, Notch1, Chromosome Aberrations, Acute leukemia, ABL, Transition (genetics), Genes, p16, digestive, oral, and skin physiology, hemic and immune systems, Hematology, Gene rearrangement, medicine.disease, Leukemia, Oncology, Immunology, psychological phenomena and processes
Abstract

Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia

Published
2006

5. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast

Author

Jan Cools, Peter Vandenberghe, Anne Hagemeijer, Lucienne Michaux, and Carlos Graux

Subjects
Cancer Research, medicine.medical_specialty, Receptors, Antigen, T-Cell, Chromosomal translocation, Thymus Gland, Biology, Molecular cytogenetics, Acute lymphocytic leukemia, Molecular genetics, medicine, Humans, Leukemia-Lymphoma, Adult T-Cell, Cell Lineage, Lymphocytes, Genetics, Chromosome Aberrations, medicine.diagnostic_test, Microarray analysis techniques, Lymphoblast, Cytogenetics, Genes, Homeobox, Hematology, Protein-Tyrosine Kinases, medicine.disease, Oncology, Fluorescence in situ hybridization, Signal Transduction
Abstract

For long, T-cell acute lymphoblastic leukemia (T-ALL) remained in the shadow of precursor B-ALL because it was more seldom, and showed a normal karyotype in more than 50% of cases. The last decennia, intense research has been carried out on different fronts. On one side, development of normal thymocyte and its regulation mechanisms have been studied in multiple mouse models and subsequently validated. On the other side, molecular cytogenetics (fluorescence in situ hybridization) and mutation analysis revealed cytogenetically cryptic aberrations in almost all cases of T-ALL. Also, expression microarray analysis disclosed gene expression signatures that recapitulate specific stages of thymocyte development. Investigations are still very much actual, fed by the discovery of new genetic aberrations. In this review, we present a summary of the current cytogenetic changes associated with T-ALL. The genes deregulated by translocations or mutations appear to encode proteins that are also implicated in T-cell development, which prompted us to review the 'normal' and 'leukemogenic' functions of these transcription regulators. To conclude, we show that the paradigm of multistep leukemogenesis is very much applicable to T-ALL and that the different genetic insults collaborate to maintain self-renewal capacity, and induce proliferation and differentiation arrest of T-lymphoblasts. They also open perspectives for targeted therapies.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results